LRATD2

Across TCGA pan-cancer cohorts, LRATD2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of LRATD2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where LRATD2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LRATD2 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

COAD, KIRC, and BLCA are the cancer types where LRATD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRATD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	II,III,IV	+1.107	<.001	11	view →
KIRC	Male	III,IV	−0.874	<.001	11	view →
BLCA	Male	All	+1.631	.003	8	view →
STAD	Male	II,III,IV	+1.657	<.001	7	view →
KICH	All	II,III,IV	−1.283	<.001	7	view →
THCA	All	All	+0.470	<.001	7	view →
LIHC	Male	All	+1.018	<.001	6	view →
BRCA	All	II,III,IV	+0.809	<.001	6	view →
LUAD	All	All	+0.549	<.001	6	view →
CHOL	Male	All	+2.421	<.001	5	view →
KIRP	Female	II,III,IV	+1.301	.007	4	view →
READ	Female	All	+1.243	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

LRATD2–COAD

Open the COAD breakdown →